Cargando...
Identifying patients eligible for PARP inhibitor treatment: from NGS-based tests to 3D functional assays
Within the past few years, poly (ADP-ribose) polymerase inhibitors (PARPi) have been added to the standard of care for cancer patients, mainly for those exhibiting specific genomic alterations in the homologous recombination (HR) pathway. Until now, patients who are eligible to receive PARPi have be...
Gardado en:
| Publicado en: | Br J Cancer |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Nature Publishing Group UK
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8257604/ https://ncbi.nlm.nih.gov/pubmed/33767416 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-021-01295-z |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|